Harmony Biosciences/$HRMY
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Harmony Biosciences
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Ticker
$HRMY
Sector
Primary listing
Employees
268
Headquarters
Website
HRMY Metrics
BasicAdvanced
$1.6B
9.23
$3.10
0.84
-
Price and volume
Market cap
$1.6B
Beta
0.84
52-week high
$40.93
52-week low
$25.52
Average daily volume
971K
Financial strength
Current ratio
3.838
Quick ratio
3.654
Long term debt to equity
19.891
Total debt to equity
22.426
Interest coverage (TTM)
13.83%
Profitability
EBITDA (TTM)
245.733
Gross margin (TTM)
78.34%
Net profit margin (TTM)
23.42%
Operating margin (TTM)
28.72%
Effective tax rate (TTM)
19.65%
Revenue per employee (TTM)
$2,880,000
Management effectiveness
Return on assets (TTM)
14.10%
Return on equity (TTM)
27.58%
Valuation
Price to earnings (TTM)
9.229
Price to revenue (TTM)
2.115
Price to book
2.13
Price to tangible book (TTM)
2.45
Price to free cash flow (TTM)
6.731
Free cash flow yield (TTM)
14.86%
Free cash flow per share (TTM)
4.244
Growth
Revenue change (TTM)
17.74%
Earnings per share change (TTM)
58.41%
3-year revenue growth (CAGR)
28.48%
3-year earnings per share growth (CAGR)
47.95%
What the Analysts think about HRMY
Analyst ratings (Buy, Hold, Sell) for Harmony Biosciences stock.
Bulls say / Bears say
In Q3 2025, WAKIX delivered $239 million in net revenue, marking a 29% increase year-over-year thanks to the addition of about 500 new patients. As a result, Harmony has raised its full-year 2025 revenue outlook to $845–$865 million (Nasdaq).
Harmony posted Q2 2025 net product revenue of $200.5 million, representing 16% annual growth, and reported GAAP net income of $39.8 million ($0.68 per share), highlighting its profitable and self-sustaining business model (ADVFN).
Harmony’s pipeline continues to show potential, with Phase 3 top-line data for ZYN002 in Fragile X syndrome expected in Q3 2025 and Phase 3 trials of Pitolisant HD for narcolepsy and idiopathic hypersomnia set to begin in Q4 2025 (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
HRMY Financial Performance
Revenues and expenses
HRMY Earnings Performance
Company profitability
HRMY News
AllArticlesVideos
Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
Business Wire2 weeks ago
Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday
Benzinga1 month ago
Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial
Reuters1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Harmony Biosciences stock?
Harmony Biosciences (HRMY) has a market cap of $1.6B as of November 04, 2025.
What is the P/E ratio for Harmony Biosciences stock?
The price to earnings (P/E) ratio for Harmony Biosciences (HRMY) stock is 9.23 as of November 04, 2025.
Does Harmony Biosciences stock pay dividends?
No, Harmony Biosciences (HRMY) stock does not pay dividends to its shareholders as of November 04, 2025.
When is the next Harmony Biosciences dividend payment date?
Harmony Biosciences (HRMY) stock does not pay dividends to its shareholders.
What is the beta indicator for Harmony Biosciences?
Harmony Biosciences (HRMY) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.